The <scp>Fractalkine‐CX3CR1</scp> Axis Regulates Non‐inflammatory Osteoclastogenesis by Enhancing Precursor Cell Survival-Reference-Cited by-同舟云学术

The Fractalkine‐CX3CR1 Axis Regulates Non‐inflammatory Osteoclastogenesis by Enhancing Precursor Cell Survival

Published:2022-09-22 Issue:10 Volume:6 Page:
ISSN:2473-4039
Container-title:JBMR Plus
language:en
Short-container-title:JBMR Plus

Author:

Kuboi Yoshikazu¹²,Kuroda Yukiko³^ORCID,Ohkuro Masayoshi²,Motoi Sotaro¹²,Tomimori Yoshiya⁴,Yasuda Hisataka⁵,Yasuda Nobuyuki¹²,Imai Toshio¹⁶^ORCID,Matsuo Koichi³^ORCID

Affiliation:

1. KAN Research Institute Inc. Kobe Japan

2. Tsukuba Research Laboratories, Eisai Co. Ltd. Tsukuba Japan

3. Laboratory of Cell and Tissue Biology Keio University School of Medicine Tokyo Japan

4. Nagahama Institute for Biochemical Science Oriental Yeast Co. Ltd. Nagahama Japan

5. Bioindustry Division Oriental Yeast Co. Ltd. Tokyo Japan

6. Laboratory of Advanced Therapeutic Target Discovery Kobe University Graduate School of Medicine Kobe Japan

Funder

Keio University

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbm4.10680

Reference43 articles.

1. Osteoclast differentiation and activation;Boyle WJ;Nature,2003

2. Reaching a Genetic and Molecular Understanding of Skeletal Development

3. Osteoclast–osteoblast communication

4. What are the peripheral blood determinants for increased osteoclast formation in the various inflammatory diseases associated with bone loss;Vries TJ;Front Immunol,2019

5. Osteoporosis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis;International Journal of Molecular Sciences;2024-04-25

2. Inhibition of CX3CL1 by treadmill training prevents osteoclast-induced fibrocartilage complex resorption during TBI healing;Frontiers in Immunology;2024-01-12

3. Monocyte chemokine receptors as therapeutic targets in cardiovascular diseases;Immunology Letters;2023-04

4. Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate;Modern Rheumatology;2023-01-21